Study of gene differential expression in colorectal cancer cells

• Main Authors: Shiau, Tzeng-Hwei, 蕭增暉
• Other Authors: Liu W.T.
• Format: Others
• Language: zh-TW
• Published: 1997
• Online Access: http://ndltd.ncl.edu.tw/handle/42615613273322661780

碩士 === 長庚醫學暨工程學院 === 醫學類 === 85 === Colorectal carcinoma has been listed as the major cause of death among cancers for most western developed nations, and as the top 3 or 4 in Taiwan area. Following the progress in medical techniques in recent years, operative mortality of colorectal carcinoma is dropped. However, low long-term survival is still the major concern. So, early diagnosis and prevention to colorectal carcinoma should be taken into consideration. Methods performed on clinical diagnosis now, including occult blood test, endoscopical check, immunostaining , and so on, are time-consuming and require some other tests to confirm the results. To get a better and more convenient way for diagnosis, specific tumor markers should be looked as the best candidate. Tumor markers such as p53, c-myc, k-ras, TGF-a, ornithine decarboxylase, blood group antigen and CEA, have been studied, but the optimal one for early diagnosis of colorectal carcinoma has not yet found. In 1992, Peng Liang and Arthur B. Pardee developed a method called mRNA differential display in which differential display in gene fragments from two different performing PAGE following RT-PCR amplification of RNA. This thesis was based on this technique. Normal and tumor tissues from colorectal carcinoma patients were collected after surgical removal. RNA was extracted and RT-PCR was performed with arbitrary primers and oligo-dT primers. Following 138 combinations (46 arbitrary primers and 3 oligo-dT primers), 32 gene fragments with differential display and 26 of which were successfully reamplified by PCR. Two gene segments in normal tissues were found to express higher intensity than those in tumor tissues with the magnitude of about 2 to 10 times. These two irregular expressions may imply the possibility as colorectal carcinoma specific markers which requires sequencing and further characterization of these gene fragments before the application on clinical trial.